![]() |
Name |
3,5-Dimethylheptan-4-one
|
Molecular Formula | C9H18O | |
IUPAC Name* |
3,5-dimethylheptan-4-one
|
|
SMILES |
CCC(C)C(=O)C(C)CC
|
|
InChI |
InChI=1S/C9H18O/c1-5-7(3)9(10)8(4)6-2/h7-8H,5-6H2,1-4H3
|
|
InChIKey |
VZXXYILNWWRSGE-UHFFFAOYSA-N
|
|
Synonyms |
3,5-Dimethylheptan-4-one; 19549-84-9; 3,5-Dimethyl-4-heptanone; 4-Heptanone, 3,5-dimethyl-; di-sec-butyl ketone; EINECS 243-150-4; SCHEMBL270073; DTXSID00871297; AKOS016009812; DB-044911; FT-0637875; A905390
|
|
CAS | 19549-84-9 | |
PubChem CID | 89181 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 142.24 | ALogp: | 2.7 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 17.1 | Aromatic Rings: | 0 |
Heavy Atoms: | 10 | QED Weighted: | 0.587 |
Caco-2 Permeability: | -4.295 | MDCK Permeability: | 0.00001420 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.025 |
30% Bioavailability (F30%): | 0.112 |
Blood-Brain-Barrier Penetration (BBB): | 0.988 | Plasma Protein Binding (PPB): | 82.78% |
Volume Distribution (VD): | 1.69 | Fu: | 20.64% |
CYP1A2-inhibitor: | 0.508 | CYP1A2-substrate: | 0.877 |
CYP2C19-inhibitor: | 0.098 | CYP2C19-substrate: | 0.896 |
CYP2C9-inhibitor: | 0.097 | CYP2C9-substrate: | 0.28 |
CYP2D6-inhibitor: | 0.017 | CYP2D6-substrate: | 0.323 |
CYP3A4-inhibitor: | 0.059 | CYP3A4-substrate: | 0.421 |
Clearance (CL): | 12.483 | Half-life (T1/2): | 0.826 |
hERG Blockers: | 0.019 | Human Hepatotoxicity (H-HT): | 0.404 |
Drug-inuced Liver Injury (DILI): | 0.748 | AMES Toxicity: | 0.022 |
Rat Oral Acute Toxicity: | 0.241 | Maximum Recommended Daily Dose: | 0.029 |
Skin Sensitization: | 0.263 | Carcinogencity: | 0.145 |
Eye Corrosion: | 0.97 | Eye Irritation: | 0.982 |
Respiratory Toxicity: | 0.653 |